We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evusheld Reduces COVID-19 Disease Severity Among Unvaccinated Adults.
- Authors
Slomski, Anita
- Abstract
The international TACKLE trial randomly assigned 910 adults with mild or moderate COVID-19 symptoms to receive a single 300-mg dose of tixagevimab plus a 300-mg dose of cilgavimab or placebo within 7 days of symptom onset. Clinical Trials Update Tixagevimab plus cilgavimab, a SARS-CoV-2-neutralizing monoclonal antibody combination marketed as Evusheld, protected nonhospitalized individuals with mild to moderate COVID-19 symptoms from progressing to severe COVID-19 or death in a clinical trial.
- Publication
JAMA: Journal of the American Medical Association, 2022, Vol 328, Issue 4, p322
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.2022.12178